CapsoVision (NASDAQ:CV) Stock Breaks Above 50-Day Moving Average - What's Next?

CapsoVision logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CapsoVision shares rose 2.8% and moved above their 50-day moving average, trading as high as $6.67 and last at $6.65, versus the average of $6.54.
  • Analyst views are mixed: two analysts rate the stock Buy, one Hold, and one Sell; MarketBeat reports an average rating of Hold and an average price target of $9.50.
  • The company reported quarterly EPS of -$0.15, matching analysts’ expectations, on revenue of $3.57 million; it also disclosed large share purchases by two major shareholders.
  • Five stocks to consider instead of CapsoVision.

CapsoVision, Inc. (NASDAQ:CV - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $6.54 and traded as high as $6.67. CapsoVision shares last traded at $6.65, with a volume of 158,139 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CV. Weiss Ratings reissued a "sell (d-)" rating on shares of CapsoVision in a report on Friday, September 25th. Benchmark restated a "speculative buy" rating on shares of CapsoVision in a research report on Friday, August 14th. Zacks Research raised CapsoVision to a "hold" rating in a research note on Monday, August 31st. Finally, Roth Capital started coverage on shares of CapsoVision in a research report on Friday, August 28th. They set a "buy" rating and a $9.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $9.50.

Read Our Latest Analysis on CV

CapsoVision Trading Up 2.8%

The company's 50-day moving average is $6.54 and its 200-day moving average is $6.37. The firm has a market cap of $356.51 million, a price-to-earnings ratio of -14.15 and a beta of -2.34.

CapsoVision (NASDAQ:CV - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). CapsoVision had a negative net margin of 210.09% and a negative return on equity of 160.23%. The business had revenue of $3.57 million during the quarter. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. Equities research analysts forecast that CapsoVision, Inc. will post -0.56 EPS for the current year.

Insiders Place Their Bets

In other CapsoVision news, major shareholder Ching Hang Shen purchased 878,734 shares of the stock in a transaction dated Tuesday, September 15th. The stock was bought at an average price of $5.69 per share, with a total value of $4,999,996.46. Following the acquisition, the insider owned 2,926,655 shares of the company's stock, valued at approximately $16,652,666.95. This represents a 42.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Eliyahou Et Al Harari purchased 1,757,469 shares of the stock in a transaction dated Friday, September 18th. The shares were acquired at an average cost of $5.69 per share, with a total value of $9,999,998.61. Following the acquisition, the insider directly owned 1,396,494 shares in the company, valued at $7,946,050.86. This represents a -486.87% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 2.30% of the company's stock.

Institutional Trading of CapsoVision

Several large investors have recently bought and sold shares of CV. Legal & General Group Plc bought a new position in shares of CapsoVision in the second quarter worth about $26,000. Connective Capital Management LLC acquired a new stake in shares of CapsoVision in the 2nd quarter valued at approximately $76,000. Bank of America Corp DE boosted its stake in shares of CapsoVision by 528.9% in the 1st quarter. Bank of America Corp DE now owns 22,238 shares of the company's stock valued at $162,000 after purchasing an additional 18,702 shares in the last quarter. Deutsche Bank AG bought a new stake in shares of CapsoVision during the 2nd quarter valued at approximately $263,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of CapsoVision during the 1st quarter valued at approximately $359,000.

CapsoVision Company Profile

(Get Free Report)

CapsoVision develops medical technology for capsule endoscopy, a method of examining the digestive tract using a swallowable camera. Its products are designed to help clinicians visualize the small intestine as part of diagnostic evaluation. The company's CapsoCam Plus system uses a swallowable capsule with multiple cameras to capture panoramic images as it moves through the small intestine. Images are stored in the capsule and later retrieved for review using the company's supporting hardware and software.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CapsoVision Right Now?

Before you consider CapsoVision, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CapsoVision wasn't on the list.

While CapsoVision currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines